Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 560 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-melanomatous Skin Cancer
Interventions
celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total lymphoid irradiation
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Stanford, California
Conditions
Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus, Squamous Cell Cancer
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Aging
Interventions
Sulforaphane, Narrow-band Ultraviolet B exposure, 4 mm skin punch biopsy
Drug · Radiation · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Dermatitis, Healthy, Neoplasm, Urticaria, Vesiculobullous Skin Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1976 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Head and Neck Neoplasms
Interventions
bevacizumab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

NCT04738149
Conditions
Vitiligo
Interventions
Bimatoprost, Excimer laser, Microneedling with a dermaroller
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Oligometastatic Lung Adenocarcinoma
Interventions
Erlotinib, Local Therapies
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Conditions
Spinal Metastases
Interventions
qMRI with Gadoteridol contrast agent
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Head and Neck Cancer
Interventions
Taxotere, Radiation therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2008
U.S. locations
4
States / cities
Boston, Massachusetts
Conditions
Dermatitis, Photoallergic
Interventions
Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Conditions
Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
Interventions
Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
Conditions
Endometrial Cancer, Cancer of the Endometrium
Interventions
TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Esophageal Cancer
Interventions
wireless pulse oximeter (Wipox)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Cetuximab, Docetaxel, Cisplatin, Fluorouracil, Radiotherapy (RT), Chemotherapy
Drug · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
Conditions
Head and Neck Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, doxorubicin hydrochloride, fosbretabulin disodium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Detroit, Michigan • Cleveland, Ohio • Pittsburgh, Pennsylvania
Conditions
Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS)
Interventions
Romiplostim
Drug
Lead sponsor
Anjali Sharathkumar
Other
Eligibility
0 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, etoposide, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
76
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 56 more
Completed Phase 2 Interventional Results available

Perioperative Therapy for Resectable Pancreatic Cancer

NCT00609336
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gemcitabine hydrochloride, docetaxel, capecitabine, intensity-modulated radiation therapy, oxaliplatin, pancreatic surgical procedure, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Non-Small Cell Lung Cancer, Radiation-Induced Cardiac Disease
Interventions
Serum Pro-N-Cadherin Biomarker Assessment, Echocardiogram
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions
alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
9
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more
Conditions
Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Embryonal Brain Tumor Not Otherwise Specified, Recurrent Ependymoma
Interventions
Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy
Biological · Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Melanoma
Interventions
Ipilimumab, Stereotactic Ablative Radiosurgery (SART)
Drug · Radiation
Lead sponsor
Wolfram Samlowski
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada